Glicksman RM, Tjong MC, Neves-Junior WFP, et al. - Because rising cancer incidence associated with improvements in systemic and local therapies extending life expectancy are translating into more people with spinal metastases. This executes the multidisciplinary management of spinal metastases and the development of new therapies increasingly important. Experts sought to review the literature from the MEDLINE database to recognize articles reporting on spinal stereotactic ablative radiotherapy (SABR) to September 30, 2018, in order to present a multidisciplinary way to appropriate individuals selection and technical considerations, and summarize current efforts to combine spinal SABR with systemic therapies. They involved 59 unique publications with 5655 people undergone SABR for spinal metastases. In the de novo setting, Spinal SABR was correlated with 1-year local control rates nearly 80% to 90%, higher than 80% in the postoperative setting, and greater than 65% in the reirradiation setting. It was found that spinal SABR might be an effective treatment choice for well-selected individuals with spinal metastases, attaining high rates of local tumor control with moderate rates of unfavorable effects. Moreover, optimal management shall hold review by a multidisciplinary care team.